2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
555
Lymphoma
447
Precursor Cell Lymphoblastic Leukemia-Lymphoma
413
Lymphoma, Large B-Cell, Diffuse
348
Leukemia
346
Multiple Myeloma
336
Lymphoma, Non-Hodgkin
317
Leukemia, Myeloid, Acute
289
Leukemia, Lymphocytic, Chronic, B-Cell
286
Lymphoma, Follicular
241
Burkitt Lymphoma
217
Myelodysplastic Syndromes
211
Lymphoma, Mantle-Cell
202
Hodgkin Disease
193
Recurrence
155
Lymphoma, B-Cell, Marginal Zone
142
Melanoma
136
Lymphoma, Large-Cell, Immunoblastic
116
Neoplasms
109
Lymphoma, B-Cell
103
Neuroblastoma
101
Neoplasms, Plasma Cell
99
Ovarian Neoplasms
96
Triple Negative Breast Neoplasms
94
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
91
Myeloproliferative Disorders
87
Hematologic Neoplasms
87
Leukemia, Myeloid, Chronic-Phase
83
Leukemia, Myeloid, Accelerated Phase
80
Leukemia, Myelomonocytic, Chronic
78
Interventions
Immunotherapy, Adoptive
2
Bevacizumab
2
tislelizumab
1
fludarabine
1
codrituzumab
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Simpson-Golabi-Behmel syndrome
×
Cyclophosphamide
×
Clear all
NCT07500220
2026-03-30
DUET-HCC
Beijing Biotech
Phase 1/2
Recruiting
30 enrolled